Liechti ME - Search Results

1

Acute psychological and neurophysiological effects of MDMA in humans.

Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Vollenweider FX, et al. Among authors: liechti me. J Psychoactive Drugs. 2002 Apr-Jun;34(2):171-84. doi: 10.1080/02791072.2002.10399951. J Psychoactive Drugs. 2002. PMID: 12691207 Review.

2

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

Vollenweider FX, Gamma A, Liechti M, Huber T. Vollenweider FX, et al. Neuropsychopharmacology. 1998 Oct;19(4):241-51. doi: 10.1016/S0893-133X(98)00013-X. Neuropsychopharmacology. 1998. PMID: 9718588 Clinical Trial.

3

Is a single dose of MDMA harmless?

Vollenweider FX, Gamma A, Liechti M, Huber T. Vollenweider FX, et al. Neuropsychopharmacology. 1999 Oct;21(4):598-600. doi: 10.1016/S0893-133X(99)00032-9. Neuropsychopharmacology. 1999. PMID: 10481844 No abstract available.

4

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.

Liechti ME, Baumann C, Gamma A, Vollenweider FX. Liechti ME, et al. Neuropsychopharmacology. 2000 May;22(5):513-21. doi: 10.1016/S0893-133X(99)00148-7. Neuropsychopharmacology. 2000. PMID: 10731626 Clinical Trial.

5

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.

Liechti ME, Vollenweider FX. Liechti ME, et al. Eur Neuropsychopharmacol. 2000 Jul;10(4):289-95. doi: 10.1016/s0924-977x(00)00086-9. Eur Neuropsychopharmacol. 2000. PMID: 10871712 Clinical Trial.

6

3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans.

Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. Gamma A, et al. Among authors: liechti me. Neuropsychopharmacology. 2000 Oct;23(4):388-95. doi: 10.1016/S0893-133X(00)00130-5. Neuropsychopharmacology. 2000. PMID: 10989265 Clinical Trial.

7

Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Liechti ME, et al. Neuropsychopharmacology. 2000 Oct;23(4):396-404. doi: 10.1016/S0893-133X(00)00126-3. Neuropsychopharmacology. 2000. PMID: 10989266 Clinical Trial.

8

The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.

Liechti ME, Vollenweider FX. Liechti ME, et al. J Psychopharmacol. 2000;14(3):269-74. doi: 10.1177/026988110001400313. J Psychopharmacol. 2000. PMID: 11106307 Clinical Trial.

9

Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.

Liechti ME, Geyer MA, Hell D, Vollenweider FX. Liechti ME, et al. Neuropsychopharmacology. 2001 Mar;24(3):240-52. doi: 10.1016/S0893-133X(00)00199-8. Neuropsychopharmacology. 2001. PMID: 11166515

10

Gender differences in the subjective effects of MDMA.

Liechti ME, Gamma A, Vollenweider FX. Liechti ME, et al. Psychopharmacology (Berl). 2001 Mar 1;154(2):161-8. doi: 10.1007/s002130000648. Psychopharmacology (Berl). 2001. PMID: 11314678 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

231 results

Search Page